Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Autor: Thompson, Charlotte, Bugatti, Serena, Bellan, Mattia, Congia, Mattia, Holroyd, Christopher, Pratt, Arthur, Cabral da Fonseca, João Eurico, White, Laura, Warren, Louise, Peel, Joanna, Hands, Rebecca, Fossati-Jimack, Liliane, Hadfield, Gaye, Thorborn, Georgina, Ramirez, Julio, Celis, Raquel, Humby, Frances a, c, Durez, Patrick d, e, Buch, Maya H f, g, Lewis, Myles J a, c, Rizvi, Hasan b, h, Rivellese, Felice a, c, Nerviani, Alessandra a, c, Giorli, Giovanni a, Mahto, Arti i, Montecucco, Carlomaurizio j, Lauwerys, Bernard d, e, Ng, Nora k, Ho, Pauline l, Bombardieri, Michele a, c, Romão, Vasco C m, n, Verschueren, Patrick o, p, Kelly, Stephen c, Sainaghi, Pier Paolo q, Gendi, Nagui r, Dasgupta, Bhaskar s, Cauli, Alberto t, Reynolds, Piero u, Cañete, Juan D v, w, Moots, Robert x, y, Taylor, Peter C z, Edwards, Christopher J aa, ab, Isaacs, John ac, ad, Sasieni, Peter ae, Choy, Ernest af, ag, Pitzalis, Costantino a, c, *
Zdroj: In The Lancet 23-29 January 2021 397(10271):305-317
Databáze: ScienceDirect